SII Seeks From DCGI Market Authorisation For India’s First qHPV Vaccine Against Cervical Cancer

Serum Institute of India (SII) has applied to the country’s drug regulator seeking market authorisation to manufacture indigenously developed India’s first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer, official sources said on Wednesday. The Pune-based firm has applied for
http://dlvr.it/SRtJQD